SOST and sclerosteosis: Accordingly, loss of the bone-specific Wnt inhibitor sclerostin (SOST) due to inactivating SOST mutations or deletion of its regulatory region lead to sclerosteosis and Van Buchem disease, marked by high BMD with skeletal deformities such as jaw and cranial enlargement (12,13,37).